PMEF
BTAI icon

Point72 Middle East FZE’s BioXcel Therapeutics BTAI Stock Holding History

Point72 Middle East FZE’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-986
Closed -$39.9K – 1524
2023
Q3 		$39.9K Buy
+986
New +$99.7K ﹤0.01% 1253

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Point72 Middle East FZE's BTAI Position: Q4 2023 in Review

Point72 Middle East FZE sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 986 shares — an estimated $39.9K sold.

Point72 Middle East FZE first reported a position in BTAI in Q3 2023 and held it in 1 quarter. The position peaked at $39.9K in Q3 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Point72 Middle East FZE reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 986 BioXcel Therapeutics shares in Q4 2023, an estimated $39.9K.
  • Point72 Middle East FZE first reported a position in BioXcel Therapeutics in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's BioXcel Therapeutics position peaked at $39.9K in Q3 2023.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.